UGT1A1*28 polymorphism predicts irinotecan‐induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

Abstract

The current data suggested that the UGT1A1*28 polymorphism may be a key determinant for predicting irinotecan-induced severe toxicities without affecting treatment outcome for patients with metastatic CRC. Further prospective studies are warranted for using this polymorphism to optimize irinotecan-based chemotherapy.